AbbVie collaborates with BioCurate to accelerate commercialisation of Australian novel early stage discoveries into new therapeutics and drugs
Read full media release here.
Read pdf version of the full media release here.
For media-related enquiries, please contact
Kate Richards
Head of Corporate Communications
Australia and New Zealand
+61 466 420 739
kate.richards@abbvie.com
2021
November
New treatment for an aggressive blood cancer available on the PBS
Read full media release here.
Read pdf version of the full media release here.
October
New treatment for debilitating rheumatic diseases listed on the PBS
Read full media release here.
Read pdf version of the full media release here.
September
VENCLEXTA® (venetoclax) has now received full registration for adult patients with newly diagnosed Acute Myeloid Leukaemia who are ineligible for intensive chemotherapy
Read full media release here.
Read pdf version of the full media release here.
September
AbbVie welcomes registration of RINVOQ® (upadacitinib) for atopic dermatitis
Read full media release here.
Read pdf version of the full media release here.
August
AbbVie reinforces “it’s the people, not the place” in their ninth year of recognition as a Great Place to Work
Read full media release here.
Read pdf version of the full media release here.
May
AbbVie welcomes registration of RINVOQ® (upadacitinib) for two new indications
Read full media release here.
Read pdf version of the full media release here.
March
New option for Australians with certain autoimmune diseases through reimbursement of HUMIRA® (adalimumab) citrate-free formulation
Read full media release here.
Read pdf version of the full media release here.
2020
December
Venclexta (venetoclax) PBS listed as first line therapy for Chronic Lymphocytic Leukaemia (CLL) patients unfit for chemotherapy
Read full media release here.
Read pdf version of the full media release here.
October
September
MAVIRET® is the first PBS listed Hepatitis C treatment available for Australians 12 years and over
Read full media release here.
Read pdf version of the full media release here.
July
New treatment for rheumatoid arthritis, RINVOQ (upadacitinib), became available on the PBS during COVID-19 lockdown
Read full media release here.
July
AbbVie reinvents ‘pharma culture’ and takes Australia’s #2 spot for Best Place to Work
Read full media release here.
May
AbbVie Completes Transformative Acquisition of Allergan
Read full media release here.
March
AbbVie Australia - Local Response to COVID-19
Read here.
January
AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory Approval of RINVOQ® (upadacitinib)
Read full media release here.
2019
December
Chris Stemple Appointed General Manager AbbVie ANZ
Read full media release here.
December
New biologic option for severe plaque psoriasis now available on Pharmaceutical Benefits Scheme
Read full media release here.
July
AbbVie welcomes Therapeutic Goods Administration (TGA) Regulatory Approval of SKYRIZI™ (risankizumab)
Read full media release here.
June
AbbVie ANZ Appoints New Medical Director
Read full media release here.
February
New targeted treatment option for patients with Chronic Lymphocytic Leukaemia (CLL) now available on the Pharmaceutical Benefits Scheme
Read full media release here.
2018
October
AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab
Read full media release here.
August
Eight-week Hepatitis C Treatment on Pharmaceutical Benefits scheme from 1st August 2018
Read full media release here.
April
Announcement: Venclexta PBS Status
Read full media release here.
February
Experts concerned Parksinon’s patients may be missing out on support in the Illawarra
Read full media release here.